Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

2024 Scrip Asia 100

Explore APAC industry trends brought to you by experts in clinical trials, manufacturing, and more.

VIEW NOW

Featured Stories


AbbVie Spends $10bn On ImmunoGen To Improve Chances In ADC Space

Despite writing down $4bn after the failure of Stemcentrx’s Rova-T, AbbVie will bet big again on the cancer antibody-drug conjugate space by paying a high premium for ImmunoGen, including Elahere and its R&D potential.

Deals Business Strategies M & A

Corporate VCs Play A Bigger Role In Hard Times

The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before.

Companies Financing Deals

Galderma Highlights Fast Onset, Durability Data For Potential Botox Rival

The company reported positive data from two Phase IIIb trials testing RelabotulinumtoxinA and said it hopes to refile a BLA for the aesthetic dermatology product soon.

Clinical Trials Business Strategies Research & Development

Asia Spotlight

Astellas India MD On Action-Packed Run Ahead, Breaking The Glass Ceiling

In an interview with Scrip, Astellas’s India chief outlines how the Japanese company expects to build out its operations in the country, with a flurry of key launches in the wings. She also shares vignettes of her own career path, which has not been a bed of roses.



India Commercial

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Finance Watch: Lilly, Fosun Reveal Strategic Investments In Start-Ups, Growth-Stage Firms

Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.

Executives On The Move: Sypre Therapeutics, Evelo Biosciences, Amylyx Pharmaceuticals And More

Recent executive moves in the industry include changes at the top at Spyre Therapeutics, Neopharmed Gentili and CytoDyn.

Stock Watch: Is Oncology Still King?

Big pharmaceutical oncology franchise sales generally grew in the third quarter of 2023, but some were transitioning through loss of exclusivity and others were not being helped by their most innovative therapies.

Pipeline Watch: 12 Approvals And Nine Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Interviews

Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’

Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.

Olema Boosts Its Partnering Position With SERD Combo Data

Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.

Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?

Akero hopes to begin Phase III study of efruxifermin this year, with 89bio working to enter Phase III with pegozafermin in 2024. But just behind them, Boston Pharmaceuticals thinks it has a convenience and immunogenicity edge.

Roivant Won’t Continue With Brepocitinib In Lupus After Phase II Failure

The company wants to focus efforts with the TYK2/JAK1 inhibitor in orphan rheumatology indications like dermatomyositis where current treatment options are inadequate.

See All
Graphics

Biotech IPOs Get Bigger, But Not Necessarily Better

The first $1bn quarter since 2021 suggests that biotech’s IPO window is opening once more. But times remain tough, and many recently listed groups have seen their valuations fall.

ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow

Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.

Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D

After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.

Top 10 Best-Selling Drugs Of Q2 2023: COVID-19 Out, HPV In

The Merck & Co vaccine for human papillomavirus Gardasil, along with Johnson & Johnson’s Darzalex for multiple myeloma, entered the ranks of the top 10 best-selling drugs globally in the second quarter. There was no product for COVID-19 in the line-up for the first time since 2020.

See All
Recent Stories

Finance Watch: Lilly, Fosun Reveal Strategic Investments In Start-Ups, Growth-Stage Firms

Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.

Pfizer’s Mixed Readout Places Doubt On Oral GLP-1 For Obesity

Twice-daily danuglipron reduced weight in a Phase IIb trial but with a poor side-effect profile and high discontinuation rates. Pfizer is working on a once-daily formulation it hopes will offer better tolerability.

Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’

Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.

Altimmune Regains Some Momentum

Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.

Nordics BioPharma Sector In Rude Health Despite Global Downturn

When it comes to building innovative pipelines and raising cash, Scandinavia is giving the rest of Europe a run for its money.

Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value

A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.

Olema Boosts Its Partnering Position With SERD Combo Data

Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.

Executives On The Move: Sypre Therapeutics, Evelo Biosciences, Amylyx Pharmaceuticals And More

Recent executive moves in the industry include changes at the top at Spyre Therapeutics, Neopharmed Gentili and CytoDyn.

Risk/Benefit Of CAR-T For Autoimmune Diseases May Shift With FDA Investigation

CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.

Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?

Akero hopes to begin Phase III study of efruxifermin this year, with 89bio working to enter Phase III with pegozafermin in 2024. But just behind them, Boston Pharmaceuticals thinks it has a convenience and immunogenicity edge.

CAR-T Safety Probe Causes Alarm, But Is Unlikely To Upend Therapies

Hopes are that the impact of the US FDA’s investigation into a small number of T-cell malignancies associated with CAR-T therapies will be small since the benefit/risk profile still looks sound.

Stock Watch: Is Oncology Still King?

Big pharmaceutical oncology franchise sales generally grew in the third quarter of 2023, but some were transitioning through loss of exclusivity and others were not being helped by their most innovative therapies.

UsernamePublicRestriction

Register